CompletedPhase 2NCT00524342
IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Studying Pseudo-von Willebrand disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Margaret Ragni
- Principal Investigator
- Margaret V. Ragni, MD, MPHUniversity of Pittsburgh Medical Center
- Intervention
- Oprelvekin, Interleukin 11, IL-11(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 18-45 years · FEMALE
- Timeline
- 2008 – 2010
Study locations (1)
- Hemophilia Center of Western PA, Pittsburgh, Pennsylvania, United States
Collaborators
University of North Carolina · Wyeth is now a wholly owned subsidiary of Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00524342 on ClinicalTrials.gov